Literature DB >> 27906870

Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: A propensity-matched analysis.

James P Byrne1, William Geerts, Stephanie A Mason, David Gomez, Christopher Hoeft, Ryan Murphy, Melanie Neal, Avery B Nathens.   

Abstract

BACKGROUND: Pulmonary embolism (PE) is a leading cause of delayed mortality in patients with severe injury. While low-molecular-weight heparin (LMWH) is often favored over unfractionated heparin (UH) for thromboprophylaxis, evidence is lacking to demonstrate an effect on the occurrence of PE. This study compared the effectiveness of LMWH versus UH to prevent PE in patients following major trauma.
METHODS: Data for adults with severe injury who received thromboprophylaxis with LMWH or UH were derived from the American College of Surgeons Trauma Quality Improvement Program (2012-2015). Patients who died or were discharged within 5 days were excluded. Rates of PE were compared between propensity-matched LMWH and UH groups. Subgroup analyses included patients with blunt multisystem injury, penetrating truncal injury, shock, severe traumatic brain injury, and isolated orthopedic injury. A center-level analysis was performed to determine if practices with respect to choice of prophylaxis type influence hospital PE rates.
RESULTS: We identified 153,474 patients at 217 trauma centers who received thromboprophylaxis with LMWH or UH. Low-molecular-weight heparin was given in 74% of patients. Pulmonary embolism occurred in 1.8%. Propensity score matching yielded a well-balanced cohort of 75,920 patients. After matching, LMWH was associated with a significantly lower rate of PE compared with UH (1.4% vs. 2.4%; odds ratio, 0.56; 95% confidence interval, 0.50-0.63). This finding was consistent across injury subgroups. Trauma centers in the highest quartile of LMWH utilization (median LMWH use, 95%) reported significantly fewer PE compared with centers in the lowest quartile (median LMWH use, 39%; 1.2% vs. 2.0%; odds ratio, 0.59; 95% confidence interval, 0.48-0.74).
CONCLUSIONS: Thromboprophylaxis with LMWH (vs. UH) was associated with significantly lower risk of PE. Trauma centers favoring LMWH-based prophylaxis strategies reported lower rates of PE. Low-molecular-weight heparin should be the anticoagulant agent of choice for prevention of PE in patients with major trauma. LEVEL OF EVIDENCE: Therapeutic study, level III.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27906870     DOI: 10.1097/TA.0000000000001321

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  11 in total

1.  Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.

Authors:  Charles A Karcutskie; Arjuna Dharmaraja; Jaimin Patel; Sarah A Eidelson; Anish B Padiadpu; Arch G Martin; Gabriel Lama; Edward B Lineen; Nicholas Namias; Carl I Schulman; Kenneth G Proctor
Journal:  JAMA Surg       Date:  2018-02-01       Impact factor: 14.766

2.  Venous thromboembolism prophylaxis and the impact of a thrombosis service at a Canadian level 1 trauma centre

Authors:  Paul T. Engels; Heather Thomas; Angela Coates; Husham Bakry; Abdulaziz Alali; Ahmad AlGhambdi; Ahmed Al-Jabri; Ahmed Bugshan
Journal:  Can J Surg       Date:  2019-12-01       Impact factor: 2.089

Review 3.  Venous Thromboembolism in Trauma: The Role of Anticoagulation and Inferior Vena Cava Filters.

Authors:  Nicholas Xiao; Kush R Desai
Journal:  Semin Intervent Radiol       Date:  2021-04-15       Impact factor: 1.513

4.  Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial.

Authors:  Molly Elizabeth Droege; Christopher Allen Droege; Carolyn Dosen Philpott; Megan Leslie Webb; Neil Edward Ernst; Krishna Athota; Devin Wakefield; Joseph Richard Dowd; Dina Gomaa; Bryce H R Robinson; Dennis Hanseman; Joel Elterman; Eric William Mueller
Journal:  J Thromb Thrombolysis       Date:  2021-05-12       Impact factor: 2.300

5.  Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement.

Authors:  Marion Wiegele; Herbert Schöchl; Alexander Haushofer; Martin Ortler; Johannes Leitgeb; Oskar Kwasny; Ronny Beer; Cihan Ay; Eva Schaden
Journal:  Crit Care       Date:  2019-02-22       Impact factor: 9.097

6.  Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithm.

Authors:  Eric J Ley; Carlos V R Brown; Ernest E Moore; Jack A Sava; Kimberly Peck; David J Ciesla; Jason L Sperry; Anne G Rizzo; Nelson G Rosen; Karen J Brasel; Rosemary Kozar; Kenji Inaba; Matthew J Martin
Journal:  J Trauma Acute Care Surg       Date:  2020-11       Impact factor: 3.313

7.  Timing of femoral shaft fracture fixation following major trauma: A retrospective cohort study of United States trauma centers.

Authors:  James P Byrne; Avery B Nathens; David Gomez; Daniel Pincus; Richard J Jenkinson
Journal:  PLoS Med       Date:  2017-07-05       Impact factor: 11.069

8.  Comparison between CT and MRI in the assessment of pulmonary embolism: A meta-analysis.

Authors:  Feng Chen; Yi-Hong Shen; Xu-Qing Zhu; Jing Zheng; Feng-Jie Wu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

9.  Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity.

Authors:  Shravan Morla; Hiroshi Deguchi; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-12-10       Impact factor: 5.824

10.  Characterizing the delays in adequate thromboprophylaxis after TBI.

Authors:  Navpreet K Dhillon; Yassar M Hashim; Naomi Berezin; Felix Yong; Geena Conde; Russell Mason; Eric J Ley
Journal:  Trauma Surg Acute Care Open       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.